Published in Curr Hepat Rep on March 01, 2013
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases. Gastroenterology (1976) 3.44
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
Risk factors for complications after performance of ERCP. Gastrointest Endosc (2002) 2.93
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med (1997) 2.41
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl (2004) 2.31
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol (2000) 2.25
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl (2000) 2.23
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Polypoid lesions of the gallbladder: diagnosis and indications for surgery. Br J Surg (1992) 2.04
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
The natural history of small-duct primary sclerosing cholangitis. Gastroenterology (2008) 1.92
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg (2004) 1.88
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol (2010) 1.80
Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology (1991) 1.73
A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl (2009) 1.72
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol (2008) 1.70
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc (2002) 1.65
Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2011) 1.63
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut (2011) 1.61
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.52
The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther (2012) 1.52
High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther (2012) 1.49
Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr (2007) 1.48
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.46
Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology (1987) 1.45
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology (2005) 1.45
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology (2007) 1.45
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology (1986) 1.43
Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical review. J Gastrointestin Liver Dis (2009) 1.41
Short- and long-term surgical outcomes in patients undergoing proctocolectomy with ileal pouch-anal anastomosis in the setting of primary sclerosing cholangitis. Dis Colon Rectum (2011) 1.41
A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A (1999) 1.37
Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis (2004) 1.34
Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology (2011) 1.28
Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant (2006) 1.26
Polypoid lesions of the gallbladder: diagnosis and followup. J Am Coll Surg (2009) 1.24
Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation (2011) 1.19
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (1992) 1.19
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.14
The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther (2005) 1.13
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.12
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut (2012) 1.11
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am (2009) 1.08
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol (2007) 1.05
Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology (2010) 1.05
Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective. Dig Dis Sci (2011) 1.05
A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography. Health Technol Assess (2004) 1.03
Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther (2012) 1.03
Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol (2011) 1.02
Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol (1997) 1.00
An update on primary sclerosing cholangitis. Curr Opin Gastroenterol (2008) 1.00
Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology (2008) 0.98
High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med (2008) 0.98
Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies? Surgery (2006) 0.97
Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis (1991) 0.96
In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol (2002) 0.96
Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther (2011) 0.96
Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet (2003) 0.95
Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol (2011) 0.93
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther (2012) 0.93
Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis (2011) 0.92
A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer (2011) 0.92
Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum (2011) 0.90
Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy (2011) 0.89
Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol (2012) 0.89
Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2010) 0.87
Infliximab for ulcerative colitis following liver transplantation. Eur J Gastroenterol Hepatol (2007) 0.85
Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2011) 0.85
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther (2011) 0.84
Adenocarcinoma in an ileoanal pouch formed for ulcerative colitis in a patient with primary sclerosing cholangitis and a liver transplant: report of a case and review of the literature. Dis Colon Rectum (2006) 0.83
Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis (2011) 0.82
Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol (2010) 0.79
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol (2008) 1.69
Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol (2004) 1.66
AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology (2013) 1.64
Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Noninvasive assessment of liver fibrosis. Hepatology (2011) 1.57
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52
Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology (2013) 1.35
Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.33
Abdominal magnetic resonance elastography. Top Magn Reson Imaging (2009) 1.26
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol (2010) 1.17
Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14
Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology (2008) 1.11
Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.09
Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.07
Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol (2007) 1.05
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology (2006) 1.00
Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol (2010) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99
Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol (2007) 0.98
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging (2015) 0.98
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2013) 0.92
Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am (2011) 0.91
Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol (2013) 0.90
Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology (2011) 0.89
Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl (2004) 0.89
Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl (2012) 0.87
Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis (2012) 0.87
Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am (2006) 0.87
Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol (2013) 0.86
Hepatic and splenic stiffness augmentation assessed with MR elastography in an in vivo porcine portal hypertension model. J Magn Reson Imaging (2013) 0.86
Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol (2006) 0.84
Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl (2013) 0.83
Risk of lymphoma in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2007) 0.82
Time trends in hospitalization and discharge status for cirrhosis and portal hypertension in the United States. Hepatology (2010) 0.82
Clinical management of autoimmune biliary diseases. J Autoimmun (2013) 0.80
Celiac disease-associated autoimmune cholangitis. Am J Gastroenterol (2002) 0.80
Cholestatic liver disease. Med Clin North Am (2013) 0.79
Economic impact of hospitalization for end-stage liver disease. Am J Gastroenterol (2002) 0.78
Methodologic issues with transfer of ultrasound-based transient elastography into clinical practice. J Hepatol (2007) 0.78
Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl (2012) 0.78
One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology (2009) 0.78
MR Elastography of Liver Disease: State of the Art. Appl Radiol (2013) 0.77
Chronic inflammation, liver stiffness, and clinical decision making: an unavoidable partnership. Clin Gastroenterol Hepatol (2012) 0.77
Acute graft-versus-host disease after liver transplantation. Transplantation (2007) 0.77
Predicting clinical outcomes with elastography in primary biliary cirrhosis: one step closer? Gastroenterology (2013) 0.76
Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep (2013) 0.76
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci (2009) 0.76
The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2013) 0.75
Role of computerized image morphometry for assessing noninvasive methods to detect hepatic fibrosis. Clin Gastroenterol Hepatol (2008) 0.75
Determining the nature and impact of fatigue after liver transplantation. Liver Transpl (2006) 0.75
Recall processes for biliary cytology in primary sclerosing cholangitis. Curr Opin Gastroenterol (2014) 0.75
Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis. Liver Int (2008) 0.75
Evening administration of long-acting beta-blockers for primary prophylaxis in cirrhosis: an effective strategy. Am J Gastroenterol (2011) 0.75
Recognizing and preventing death from compensated cirrhosis in the community. Liver Int (2011) 0.75
Quantitative dynamic contrast-enhanced magnetic resonance imaging for assessing treatment response in hepatocellular carcinoma. Gastroenterology (2008) 0.75
Functional hepatic imaging and disease recurrence after liver transplantation. Liver Transpl (2006) 0.75
Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes. Hepatology (2008) 0.75
Markov models in primary biliary cirrhosis. Gastroenterology (2002) 0.75
Polluting the pathogenesis of primary biliary cirrhosis. Hepatology (2006) 0.75
Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep (2015) 0.75
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. Am J Manag Care (2016) 0.75
A 48-year-old woman with a new diagnosis of autoimmune hepatitis. Clin Gastroenterol Hepatol (2012) 0.75